NeuExcell Therapeutics, a Sino-US biotech company specializing in treatments for neurological damage and degenerative diseases, has successfully raised over RMB 100 million (USD 14.5 million) in a pre-Series A+ financing round. The funding round saw participation from notable investors such as ZJ Leading VC, Jemincare, HX Pharma, Leader Venture Capital, Suzhou Suxin Yihe Investment Management, Huiju Xinxing Fund, CSTC, and Redrock Capital. The capital raised will be allocated to accelerate the clinical transformation of the company’s in situ nerve regeneration technology.
Product Pipeline and Expertise
Founded by the globally recognized expert in regenerative medicine, Dr. Chen Gong, NeuExcell Therapeutics has an extensive product pipeline addressing a range of neurological conditions. These include stroke, glioblastoma, Huntington’s disease, Alzheimer’s disease, Parkinson’s disease, traumatic brain injury, spinal cord injury, and ophthalmic diseases. The company’s focus on innovative therapies for these conditions underscores its commitment to improving patient outcomes in the field of neurology.
Investment in Clinical Transformation
The proceeds from this financing round will be instrumental in advancing NeuExcell Therapeutics’ clinical development efforts. The investment will support the company’s mission to bring its in situ nerve regeneration technology from the lab to the clinic, potentially revolutionizing treatment options for patients suffering from a variety of neurological disorders.-Fineline Info & Tech
